STAT6 degrader
Kymera Soars on Early Protein Degrader Data
Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease
Actionable Insights Powered by AI
Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease